Supriya Lifescience Limited has issued a postal ballot notice dated February 09, 2026, seeking shareholder approval for the appointment and re-appointment of independent directors. The company has proposed three special resolutions for consideration through remote e-voting, demonstrating its commitment to strengthening board governance and independence.

Director Appointment Proposals

The postal ballot notice outlines three key appointments that require shareholder approval through special resolutions:

All three directors will serve as Non-Executive Independent Directors for five consecutive years and will not be liable to retire by rotation. The Board of Directors appointed Mr. Panchal and Mr. Hari as Additional Directors on February 09, 2026, following recommendations from the Nomination and Remuneration Committee.

Voting Process and Timeline

The company has established a comprehensive e-voting framework in compliance with regulatory requirements. The remote e-voting period is scheduled as follows:

The company has engaged National Securities Depository Limited (NSDL) to provide remote e-voting facilities to shareholders. Only members whose names appear in the Register of Members or List of Beneficial Owners as on the cut-off date will be eligible to vote.

Director Profiles and Expertise

Mr. Manish Panchal brings over 32 years of cross-industry experience spanning chemicals, logistics, pharmaceuticals, medical devices, and healthcare sectors. His expertise includes strategy and innovation, operational excellence, business development, and P&L management. He holds advanced qualifications from prestigious institutions including Asian Institute of Management and Stanford University Graduate School of Business.

Mr. Kothandaraman Hari is a capital markets professional with over 28 years of experience, having contributed significantly to the National Stock Exchange of India's growth as Executive Vice President. He is a qualified Cost Accountant and Company Secretary, currently serving as founder of Onspin Consultants LLP.

Dr. Neelam Arora possesses over 31 years of teaching experience and 10 years of administrative experience in education. She holds advanced degrees including M.Com, L.L.M., and Ph.D., bringing valuable expertise in commerce, taxation, economics, and law to the board.

Regulatory Compliance

The postal ballot process adheres to multiple regulatory frameworks including Section 110 of the Companies Act, 2013, SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and various Ministry of Corporate Affairs circulars. All proposed directors have submitted declarations confirming their independence criteria and eligibility for appointment as Independent Directors.

The company will communicate results to BSE Limited and National Stock Exchange of India Limited, where its equity shares are listed, and make them available on the company website and NSDL's e-voting portal following the declaration.

Supriya Lifescience Limited delivered a steady performance in Q3 FY26, reporting revenue of INR206 crores with 11% year-on-year growth. The pharmaceutical company maintained strong profitability metrics while advancing its product launch pipeline and facility expansion plans during the quarter ended December 31, 2025.

Financial Performance Highlights

The company's quarterly results demonstrated consistent operational execution across key financial metrics:

For the nine-month period, revenue stood at INR551 crores compared to INR512 crores in 9M FY25, reflecting 8% year-on-year growth. EBITDA reached INR196 crores against INR193 crores in the previous year, with margins maintained at 36% for 9M FY26.

Export Markets Drive Growth

Exports remained the cornerstone of the company's revenue strategy, contributing 82% of Q3 revenues. The geographic diversification showed positive momentum with Latin America delivering healthy growth and accounting for 24% of quarterly revenues. North America contributed 6% to total revenues, with both regions demonstrating increased overall revenue contribution during the quarter.

The company's backward integration initiatives continued to strengthen its cost structure, with 74% of revenues coming from backward integrated products. This strategic focus supports sustainable growth while enhancing operational efficiency across the product portfolio.

Product Launch Pipeline Progress

Supriya Lifescience successfully executed its planned product launches during Q3 FY26. The company launched a key cardiovascular product expected to contribute meaningfully in Q4 FY26, along with an ADHD product anticipated to scale up over coming quarters. The liquid anaesthetics product has been commercialized with steady monthly supplies underway.

Development activities for the contrast media product continue progressing as planned, supporting the company's strategy of introducing 3-4 new products annually. These launches align with the company's focus on high-margin niche offerings across core therapeutic segments including anesthetics, anti-diabetics, anti-anxiety medications, vitamins, and ADHD treatments.

Facility Development and Expansion

The Ambernath facility reached a significant milestone, becoming ready for capitalization in Q4 FY26. This development marks the completion of commissioning and readiness for sustained commercial operations, representing a key advancement for the company's CDMO segment.

Capex for Q3 FY26 stood at INR28 crores, while nine-month capex reached INR71 crores, primarily directed toward the Ambernath facility. Management expects remaining FY26 capex of approximately INR15 crores, focused on maintenance capex and specific projects including the Ribo Block and formulation plant requirements.

Management Guidance and Outlook

Management reaffirmed its guidance of approximately 20% annual revenue growth and EBITDA margins of 33-35%. The company remains confident in its progress toward the INR1,000 crores revenue milestone for FY27, supported by a healthy pipeline of planned launches and steady demand across core therapeutic segments.

Dr. Satish Wagh, Executive Chairman, emphasized the company's strategic positioning: "Our focus on operational efficiency and high-margin niche offerings have delivered strong execution. We remain focused on scaling our presence in regulated markets and reinforcing our competitive position through backward integration, strong regulatory capabilities and a diverse product portfolio."